Cite
Kume H, Kawai T, Nagata M, et al. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2014;3(2):303-307doi: 10.3892/mco.2014.469.
Kume, H., Kawai, T., Nagata, M., Azuma, T., Miyazaki, H., Suzuki, M., Fujimura, T., Nakagawa, T., Fukuhara, H., & Homma, Y. (2015). Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Molecular and clinical oncology, 3(2), 303-307. https://doi.org/10.3892/mco.2014.469
Kume, Haruki, et al. "Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer." Molecular and clinical oncology vol. 3,2 (2015): 303-307. doi: https://doi.org/10.3892/mco.2014.469
Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H, Homma Y. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2015 Mar;3(2):303-307. doi: 10.3892/mco.2014.469. Epub 2014 Dec 01. PMID: 25798258; PMCID: PMC4360872.
Copy
Download .nbib